We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton (BDX) to Expand Syringe Capacity at Holdrege Facility
Read MoreHide Full Article
Leading global medical technology company Becton, Dickinson and Company (BDX - Free Report) announced that it is expanding capacity at its Holdrege, NE facility. The capacity expansion would cost $100 million and be directed toward insulin syringe manufacturing operations. The company already produces more than two billion insulin syringes annually. This averages to production of more than 250,000 syringes per hour.
BD began operations in Holdrege in 1966 in a 12,000-square-foot building with 66 associates. Gradually, the facility has grown to 350,000 square feet with more than 650 associates manufacturing 20 different products.
Based in Franklin Lakes, NJ, Becton, Dickinson, popularly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
An innovative product pipeline is the key growth driver at BD. A huge number of regulatory approvals both in the U.S. and international markets are facilitating expansion of the company’s product portfolio. The company also has a partnership with Central Admixture Pharmacy Services (CAPS) under which BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre-filled anesthesia syringes.
We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results. Although the Zacks Consensus Estimate for the full year has remained unchanged at $8.56 over the last seven days, it reflects year-over-year growth of almost 19.6%.
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include GW Pharmaceuticals plc , NuVasive, Inc. and Baxter International Inc. (BAX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
GW Pharmaceuticals consistently surpassed expectations in the last four quarters, with an average positive surprise of 41.67%. This represents an impressive year-to-date return of approximately 58.1%, better than the S&P 500’s 6.5% over the same period.
NuVasive also has a steady record in beating earnings expectations over the last four quarters, with an average positive surprise of 18.98%. This represents an impressive year-to-date return of approximately 25.78%, better than the S&P 500’s 6.5% over the same period.
Finally, Baxter International also surpassed expectations in each of the last four quarters, with an average positive surprise of 30.55%. This represents an impressive year-to-date return of approximately 26.34%, better than the S&P 500’s 6.5% over the same period. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Becton (BDX) to Expand Syringe Capacity at Holdrege Facility
Leading global medical technology company Becton, Dickinson and Company (BDX - Free Report) announced that it is expanding capacity at its Holdrege, NE facility. The capacity expansion would cost $100 million and be directed toward insulin syringe manufacturing operations. The company already produces more than two billion insulin syringes annually. This averages to production of more than 250,000 syringes per hour.
BD began operations in Holdrege in 1966 in a 12,000-square-foot building with 66 associates. Gradually, the facility has grown to 350,000 square feet with more than 650 associates manufacturing 20 different products.
Based in Franklin Lakes, NJ, Becton, Dickinson, popularly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
An innovative product pipeline is the key growth driver at BD. A huge number of regulatory approvals both in the U.S. and international markets are facilitating expansion of the company’s product portfolio. The company also has a partnership with Central Admixture Pharmacy Services (CAPS) under which BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre-filled anesthesia syringes.
BECTON DICKINSO Price
BECTON DICKINSO Price | BECTON DICKINSO Quote
We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results. Although the Zacks Consensus Estimate for the full year has remained unchanged at $8.56 over the last seven days, it reflects year-over-year growth of almost 19.6%.
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include GW Pharmaceuticals plc , NuVasive, Inc. and Baxter International Inc. (BAX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
GW Pharmaceuticals consistently surpassed expectations in the last four quarters, with an average positive surprise of 41.67%. This represents an impressive year-to-date return of approximately 58.1%, better than the S&P 500’s 6.5% over the same period.
NuVasive also has a steady record in beating earnings expectations over the last four quarters, with an average positive surprise of 18.98%. This represents an impressive year-to-date return of approximately 25.78%, better than the S&P 500’s 6.5% over the same period.
Finally, Baxter International also surpassed expectations in each of the last four quarters, with an average positive surprise of 30.55%. This represents an impressive year-to-date return of approximately 26.34%, better than the S&P 500’s 6.5% over the same period. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>